Trial Profile
Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 14 Feb 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 07 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.
- 31 Jan 2023 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.